详细说明
- Species ReactivityHuman
- SpecificityDetects human EphA2 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant mouse EphA4, A5, A6, A7, A8, or recombinant rat EphB1 is observed.
- SourceMonoclonal Mouse IgG 2A Clone # 371805
- PurificationProtein A or G purified from hybridoma culture supernatant
- ImmunogenMouse myeloma cell line NS0-derived recombinant human EphA2
Gln25-Asn534
Accession # P29317 - FormulationLyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
- LabelUnconjugated
- Recommended
ConcentrationSample
- Western Blot1 µg/mLRecombinant Human EphA2 (Catalog # ) under non-reducing conditions only
- Flow Cytometry0.25 µg/10 6 cellsSee below
- CyTOF-readyReady to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
- Immunocytochemistry8-25 µg/mLSee below
Flow Cytometry | Detection of EphA2 in A431 Human Cell Line by Flow Cytometry. A431 human epithelial carcinoma cell line was stained with Mouse Anti-Human EphA2 Monoclonal Antibody (Catalog # MAB3035, filled histogram) or isotype control antibody (Catalog # , open histogram), followed by Phycoerythrin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # ). View our protocol for . |
Immunocytochemistry | EphA2 in A431 Human Cell Line. EphA2 was detected in immersion fixed A431 human epithelial carcinoma cell line using Mouse Anti-Human EphA2 Monoclonal Antibody (Catalog # MAB3035) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # ) and counterstained with DAPI(blue). Specific staining was localized to the cell surface. View our protocol for . |
- ReconstitutionReconstitute at 0.5 mg/mL in sterile PBS.
- ShippingThe product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
- Stability & StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
EphA2, also known as Eck, Myk2, and Sek2, is a member of the Eph receptor tyrosine kinase family which binds Ephrins A1, 2, 3, 4, and 5 (1, 2, 3, 4). A and B class Eph proteins have a common structural organization. The human EphA2 cDNA encodes a 976 amino acid (aa) precursor including a 24 aa signal sequence, a 510 aa extracellular domain (ECD), a 24 aa transmembrane segment, and a 418 aa cytoplasmic domain. The ECD contains an N-terminal globular domain, a cysteine-rich domain, and two fibronectin type III domains (5). The cytoplasmic domain contains a juxtamembrane motif with two tyrosine residues, which are the major autophosphorylation sites, a kinase domain, and a sterile alpha motif (SAM) (5). The ECD of human EphA2 shares 90‑94% aa sequence identity with mouse, bovine, and canine EphA2, and approximately 45% aa sequence identity with human EphA1, 3, 4, 5, 7, and 8. EphA2 becomes autophosphorylated following ligand binding (6, 7) and then interacts with SH2 domain-containing PI3-kinase to activate MAPK pathways (8, 9). Reverse signaling is also propagated through the Ephrin ligand. Transcription of EphA2 is dependent on the expression of E-Cadherin (10), and can be induced by p53 family transcription factors (11). EphA2 is upregulated in breast, prostate, and colon cancer vascular endothelium. Its ligand, EphrinA1, is expressed by the local tumor cells (12, 13). In some cases, EphA2 and EphrinA1 are expressed on the same blood vessels (14). EphA2 signaling cooperates with VEGF receptor signaling in promoting endothelial cell migration (13). The gene encoding human EphA2 maps to a region on chromosome 1 which is frequently deleted in neuroectodermal tumors (15).
- References:
- Poliakov, A. et al. (2004) Dev. Cell 7:465.
- Surawska, H. et al. (2004) Cytokine Growth Factor Rev. 15:419.
- Pasquale, E.B. (2005) Nat. Rev. Mol. Cell Biol. 6:462.
- Davy, A. and P. Soriano (2005) Dev. Dyn. 232:1.
- Bohme, B et al. (1993) Oncogene 8:2857.
- Pandey, A. et al. (1995) Science 268:567.
- Bartley, T.D. et al. (1994) Nature 368:558.
- Pandey, A. et al. (1994) J. Biol. Chem. 269:30154.
- Miao, H. et al. (2001) Nat. Cell Biol. 3:527.
- Orsulic, S. and R. Kemler (2000) J. Cell Sci. 113:1793.
- Dohn, M. et al. (2001) Oncogene 20:6503.
- Zelinski, D.P. et al. (2001) Cancer Res. 61:2301.
- Brantley, D.M. et al. (2002) Oncogene 21:7011.
- Ogawa, K. et al. (2000) Oncogene 19:6043.
- Sulman, E.P. et al. (1997) Genomics 40:371.
- Entrez Gene IDs:1969 (Human); 13836 (Mouse)
- Alternate Names:ARCC2; EC 2.7.10; EC 2.7.10.1; Eck; ECKepithelial cell receptor protein tyrosine kinase; EPH receptor A2; EphA2; ephrin type-A receptor 2; Epithelial cell kinase; Myk2; Sek2; soluble EPHA2 variant 1; Tyrosine-protein kinase receptor ECK